GS Investments Inc. Sells 355 Shares of Stryker Co. (NYSE:SYK)

GS Investments Inc. cut its stake in shares of Stryker Co. (NYSE:SYK) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,301 shares of the medical technology company’s stock after selling 355 shares during the period. Stryker makes up approximately 2.5% of GS Investments Inc.’s investment portfolio, making the stock its 12th largest holding. GS Investments Inc.’s holdings in Stryker were worth $5,509,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new position in Stryker during the 3rd quarter worth approximately $362,000. Empowered Funds LLC boosted its position in shares of Stryker by 6.5% during the third quarter. Empowered Funds LLC now owns 6,504 shares of the medical technology company’s stock worth $2,350,000 after purchasing an additional 399 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Stryker by 6.9% in the 3rd quarter. Thrivent Financial for Lutherans now owns 93,239 shares of the medical technology company’s stock valued at $33,683,000 after buying an additional 5,995 shares during the period. Caprock Group LLC raised its stake in Stryker by 2.8% during the 3rd quarter. Caprock Group LLC now owns 8,611 shares of the medical technology company’s stock worth $3,118,000 after buying an additional 234 shares during the period. Finally, Prospera Financial Services Inc lifted its holdings in Stryker by 0.5% during the third quarter. Prospera Financial Services Inc now owns 15,606 shares of the medical technology company’s stock worth $5,640,000 after acquiring an additional 81 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $378.06 on Thursday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a 50 day moving average of $383.99 and a 200-day moving average of $373.85. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $144.26 billion, a P/E ratio of 48.72, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company earned $3.46 EPS. As a group, equities research analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.89%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analyst Ratings Changes

SYK has been the subject of several recent analyst reports. Truist Financial increased their price target on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Citigroup reiterated a “buy” rating and issued a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.